Wegovy now available as $149 pill in U.S.

Wegovy’s oral pill reached U.S. pharmacies after FDA approval in December 2025, and the 1.5 mg starter dose is priced at $149 per month with higher doses running up to $299.

Wegovy is now available as a daily oral pill in U.S. pharmacies after FDA approval in December 2025. Novo Nordisk manufactures the pill and it contains semaglutide, the same active ingredient as the injectable version. The launch is noteworthy because obesity affects more than 100 million Americans and this provides a non‑injectable treatment option. What we know: - The pill became available in U.S. pharmacies on Monday following FDA approval in December 2025. - Novo Nordisk lists the 1.5 mg starter dose at $149 per month, some higher doses at $299 per month, and says insured patients may pay as little as $25 per month through a savings program. - Novo Nordisk cited results from the phase 3 OASIS 4 trial showing an average 14% weight loss over 64 weeks for people taking the pill versus 2% for placebo when combined with reduced-calorie diet and exercise, with up to 17% observed in people who remained on treatment. - The pill is taken on an empty stomach with a small amount of water and a 30-minute wait before eating or taking other medicines; common side effects reported include nausea, diarrhea, and vomiting, and it is not recommended for those under 18 or people with certain thyroid cancer histories. Summary: The introduction of the Wegovy pill expands non-injectable prescription options and is expected to affect demand for weight-loss treatments. Undetermined at this time.